LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

X-Ray Crystallography Study Reveals Structure of the Chemokine Receptor CXCR4 in Complex with a Viral Ch

By LabMedica International staff writers
Posted on 01 Feb 2015
Print article
Image: The newly solved structure of the CXCR4 receptor (black) in complex with a chemokine (purple surface). The background shows cell migration, a process driven by chemokines interacting with receptors on cell surfaces (Photo courtesy of Katya Kadyshevskaya, University of Southern California).
Image: The newly solved structure of the CXCR4 receptor (black) in complex with a chemokine (purple surface). The background shows cell migration, a process driven by chemokines interacting with receptors on cell surfaces (Photo courtesy of Katya Kadyshevskaya, University of Southern California).
The crystal structure of the protein complex created by the binding of the cellular receptor CXCR4 (C-X-C chemokine receptor-4) to its ligand has been solved by exploiting the binding characteristics of the viral chemokine analog vMIP-II.

CXCR4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12), a molecule with potent chemotactic activity for lymphocytes. This receptor is one of several chemokine receptors that HIV can use to infect CD4+ T-cells. During embryogenesis CXCL12 directs the migration of hematopoietic cells from fetal liver to bone marrow and the formation of large blood vessels. In adulthood, CXCL12 plays an important role in angiogenesis by recruiting endothelial progenitor cells (EPCs) from the bone marrow through a CXCR4 dependent mechanism. It is this function of CXCL12 that makes it a very important factor in carcinogenesis and the formation of new blood vessels that is linked to tumor progression. CXCL12 also has a role in tumor metastasis where cancer cells that express the receptor CXCR4 are attracted to metastasis target tissues that release the ligand, CXCL12.

vMIP-II (also called vCCL2) is a viral chemokine analog that is produced by Human herpesvirus 8. This protein is unique because it binds to a wide range of chemokine receptors even across different subfamilies: it binds to CCR1, CCR2, CCR5, CXCR4 (as an antagonist), and to CCR3 and CCR8 as an agonist.

The structural basis of receptor-chemokine recognition has been a long-standing unanswered question due to the challenges of structure determination for membrane protein complexes. However, investigators at the University of California, San Diego (USA) and their colleagues at the University of Southern California (Los Angeles, USA) have now reported the crystal structure of the chemokine receptor CXCR4 in complex with the viral chemokine antagonist vMIP-II at a resolution of 0.31 nm.

To overcome the difficulties of determining the structure of a membrane protein complex, the investigators combined computational modeling and disulfide trapping to vMIP-II to stabilize the complex. Once stabilized, X-ray crystallography was used to determine the three-dimensional atomic structure for the CXCR4-chemokine complex.

Results published in the January 22, 2015, online edition of the journal Science revealed that each receptor bound a single chemokine molecule, and that the interaction between the receptor and the ligand was more extensive than previously supposed, as there was a single large contiguous binding surface rather than two separate binding sites.

"This new information could ultimately aid the development of better small molecular inhibitors of CXCR4-chemokine interactions—inhibitors that have the potential to block cancer metastasis or viral infections," said senior author Dr. Tracy M. Handel, professor of pharmacology at the University of California, San Diego.

Related Links:

University of California, San Diego
University of Southern California


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more